The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

12 articles for P Gunaga


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
N6-substituted D-4'-thioadenosine-5'-methyluronamides: potent and selective agonists at the human A3 adenosine receptor.EBI
Ewha Womans University
Discovery of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor for the Treatment of Heart Failure.EBI
Bristol Myers Squibb
Discovery of a new nucleoside template for human A3 adenosine receptor ligands: D-4'-thioadenosine derivatives without 4'-hydroxymethyl group as highly potent and selective antagonists.EBI
Ewha Womans University
Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-uronamides as highly potent and selective agonists at the human A3 adenosine receptor.EBI
Ewha Womans University
Discovery of 5-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine as a Potent I Kur Inhibitor.EBI
Bristol-Myers Squibb
Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies.EBI
Bristol-Myers Squibb Research and Development
Selective IEBI
Bristol-Myers Squibb
Imidazopyrazinones as PDE1 inhibitorsBDB
H. Lundbeck
Therapeutically active compounds and their methods of useBDB
Agios Pharmaceuticals
MU opioid receptor modulatorsBDB
University of California
Methods using HDAC11 inhibitorsBDB
Forma Therapeutics
Structure-guided development of specific pyruvate dehydrogenase kinase inhibitors targeting the ATP-binding pocket.BDB
University of Texas Southwestern Medical Center